Advertisement

Marqueurs tumoraux et tumeurs germinales du testicule

  • D. Bellet
  • F. Troalen
Chapter
  • 198 Downloads
Part of the Monographies en urologie book series (MONOGRAPHIES)

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. 1.
    Bosl GJ, Motzer J (1997) Testicular germ-cell cancer. New Eng J Med 337: 242–53PubMedGoogle Scholar
  2. 2.
    International Germ Cell Cancer Collaboration Group (1997) International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15: 594–603Google Scholar
  3. 3.
    Horwich A, Huddart R, Dearnaley D (1998) Markers and management of germ-cell tumours of the testes. Lancet 352: 1535–8PubMedCrossRefGoogle Scholar
  4. 4.
    Eschwege P, Benoit G (2002) Tumeurs du testicule. Rev Prat 52: 1119–24PubMedGoogle Scholar
  5. 5.
    Korhonen J, Afthan H, Ylostalo P et al. (1997) Disappearance of human chorionic gonadotropin and its α and β-subunits after term pregnancy. Clin Chem 43: 2155–63PubMedGoogle Scholar
  6. 6.
    Bidart JM, Bellet D (1993) Human Chorionic Gonadotropin: Molecular forms, detection and clinical implications. Trends Endocrinol Metab 4: 285–91PubMedGoogle Scholar
  7. 7.
    Bellet D, Lazar V, Bieche I et al. (1997) Malignant transformation of nontrophoblastic cells is associated with the expression of chorionic gonadotropin beta genes normally transcribed in trophoblastic cells. Cancer Res 57: 516–23PubMedGoogle Scholar
  8. 8.
    Berger P, Sturgeon C, Bidart JM et al. (2002) The ISOBM TD-7 workshop on hCG and related molecules. Tumor Biol 23: 1–38CrossRefGoogle Scholar
  9. 9.
    Ozturk M, Bellet D, Manil L et al. (1987) Physiological studies of human chorionic gonadotropin (hCG), αhCG, and βhCG as measured by specific monoclonal immunoradiometric assays. Endocrinology 120: 549–55PubMedGoogle Scholar
  10. 10.
    Bellet D, Ozturk M, Bidart JM et al. (1986) Sensitive and specific assay for human chorionic gonadotropin (hCG) based on anti-peptide and anti-hCG monoclonal antibodies: construction and clinical implications. J Clin Endocrinol Metab 63: 1319–27PubMedCrossRefGoogle Scholar
  11. 11.
    Afthan H, Haglund C, Dabek J et al. (1992) Concentrations of human choriogonadotropin, its β-subunit and the core fragment of the β-subunit in serum and urine of men and nonpregnant women. Clin Chem 38: 1981–7Google Scholar
  12. 12.
    Keller RH, Lyman S (1982) α-foetoprotein: biological and clinical potential. In: Rhodes BA, ed. Tumor imaging. New York: Masson Publishing: 41–52Google Scholar
  13. 13.
    Kamoto T, Satomura S, Yoshiki T et al. (2002) Lectin-reactive alpha-foetoprotein (AFPL3 %) curability and prediction of clinical course after treatment of non-seminomatous germ cell tumors. Jpn J Clin Oncol 32: 472–6PubMedCrossRefGoogle Scholar
  14. 14.
    Bellet D, Wands JR, Isselbacher KJ et al. (1984) Serum α-foetoprotein levels in human disease: perspective from a highly specific monoclonal radioimmunoassay. Proc Natl Acad Sci USA 8: 3869–73Google Scholar
  15. 15.
    Liu F, Fritscher HA, Trujillo JM et al. (1982) Serum lactate deshydrogenase isoenzyme 1 in patients with advanced testicular cancer. Am J Clin Path 78: 178–82PubMedGoogle Scholar
  16. 16.
    Schmoll HJ, Beyer J, Pro J (1998) Prognostic factors in metastatic germ cell tumors. Semin Oncol 25: 174–86PubMedGoogle Scholar
  17. 17.
    Koshida K, Nishino A, Yamamoto H et al. (1991) The role of alkaline phosphatase isoenzymes as tumor markers for testicular germ cell tumors. J Urol 146: 47–60Google Scholar
  18. 18.
    Tandstad T, Klepp O (2003) Neuron-specific enolase in testicular cancer. Acta Oncol 42: 202–6PubMedCrossRefGoogle Scholar
  19. 19.
    Treatment of testicular cancer (1985) Lancet: 258–9Google Scholar
  20. 20.
    Oliver RTD (1985) Factors contributing to delay in diagnosis of testicular tumours. Br Med J 290: 356CrossRefGoogle Scholar
  21. 21.
    Steele JPC, Oliver RTD (2002) Testicular cancer: perils of very late presentation. Lancet 359: 1632–3PubMedCrossRefGoogle Scholar
  22. 22.
    Bellet D, Ranke A, Bressac B et al. (1989) Intérêt de l’alpha-foetoprotéine, de l’hormone chorionique gonadotrope et de sa sous-unité bêta libre pour le diagnostic, le pronostic et la surveillance des tumeurs germinales du testicule. In: Les marqueurs tumoraux, M Bolla et P Martin (Eds), Masson: 81–8Google Scholar
  23. 23.
    Hoshi S, Suzuki K, Ishidoya S et al. (2000) Significance of simultaneous determination of serum human chorionic gonadotropin (hCG) and hCG-beta in testicular tumor patients. Int J Urol 7: 218–23PubMedCrossRefGoogle Scholar
  24. 24.
    Mencel PJ, Motzer RJ, Mazumdar M et al. (1994) Advanced seminoma: treatment, results, survival, and prognosis factors in 142 patients. J Clin Oncol 12: 120–6PubMedGoogle Scholar
  25. 25.
    Canil CM, Tannock IF (2002) Doctor’s dilemma: incorporating tumor markers into clinical decision-making. Semin Oncol 29: 286–93PubMedCrossRefGoogle Scholar
  26. 26.
    Mazumdar M, Bajorin DF, Bacik J et al. (2001) Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotropin and alpha-foetoprotein during therapy. J Clin Oncol 19: 2534–41PubMedGoogle Scholar
  27. 27.
    Toner GC, Geller CK, Tan C et al. (1990) Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in non seminomatous germ cell tumors. Cancer Res 50: 5904–10PubMedGoogle Scholar
  28. 28.
    Gerl A, Lamerz R, Clemm C et al. (1996) Does serum tumor marker half-life complement pretreatment risk stratification in metastatic nonseminomatous germ cell tumors? Clin Cancer Res 2: 1565–70PubMedGoogle Scholar
  29. 29.
    Picozzi VJ, Freiha FS, Hannigan JF et al. (1984) Prognostic significance of a decline in serum human chorionic gonadotropin levels after initial chemotherapy for advanced germcell carcinoma. Ann Intern Med 100: 183–6PubMedGoogle Scholar
  30. 30.
    Horwich A, Peckham MJ (1986) Transient tumor marker elevation following chemotherapy for germ cell tumors of the testis. Cancer Treat Rep 70: 1329–31PubMedGoogle Scholar
  31. 31.
    Vogelzang NJ, Lange PH, Goldman A et al. (1982) Acute changes of α-foetoprotein and human chorionic gonadotropin during induction chemotherapy of germ cell tumors. Cancer Res 42: 4855–61PubMedGoogle Scholar
  32. 32.
    Horwich A, Peckham MJ (1984) Serum tumour marker regression rate following chemotherapy for malignant teratoma. Eur J Cancer Clin Oncol 20: 1463–70PubMedCrossRefGoogle Scholar
  33. 33.
    Droz JP, Kramar A, Nichols CR et al. (1995) Second line chemotherapy with ifosfamide, cisplatin and either etoposide or vinblastine in recurrent germ cell cancer: Assignment of prognosis groups. Proc Am Soc Clin Oncol 12: 229 (abstr 704)Google Scholar
  34. 34.
    Murphy BA, Motzer RJ, Mazumdar M et al. (1994) Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy. Cancer 73: 2520–6PubMedGoogle Scholar
  35. 35.
    Sturgeon C (2002) Practice guidelines for tumor marker use in the clinic. Clin Chem 48: 1151–9PubMedGoogle Scholar
  36. 36.
    Morris MJ, Bosl GJ (2000) Recognizing abnormal marker results that do not reflect disease in patients with germ cell tumors. J Urol 163: 796–801PubMedGoogle Scholar
  37. 37.
    Coppacks S, Newlands ES, Dent J et al. (1983) Problems of interpretation of serum concentrations of alpha-foetoprotein (AFP) in patients receiving cytotoxic chemotherapy for malignant germ cell tumours. Br J Cancer 48: 335–40Google Scholar
  38. 38.
    Grem JL, Trump DL (1986) Reversible increase in serum α-foetoprotein content associated with hepatic dysfunction during chemotherapy for seminoma. J Clin Oncol 4: 41–5PubMedGoogle Scholar
  39. 39.
    Pandha HS, Wasan HS, Harrington K et al. (1995) Lesson of the week: failure of normalisation of (alpha) foetoprotein concentration after successful treatment of teratoma. BMJ 311: 434–5PubMedGoogle Scholar
  40. 40.
    Flechon A, Droz JP (2001) Hereditary persistence of α-foetoprotein in testis disease. J Urol 165: 2004PubMedGoogle Scholar
  41. 41.
    Braunstein GD (2002) False-positive serum human chorionic gonadotropin results: causes, characteristics, and recognition. Am J Obstet Gynecol 187: 217–24PubMedCrossRefGoogle Scholar
  42. 42.
    Mills JN, Nguyen TT, Williams RD (2001) Falsely increased β-human chorionic gonadotropin with a testicular epidermoid cyst. 166: 2314Google Scholar
  43. 43.
    Bulger KN, Hesketh PJ, Babayan RK (1989) Discordant human chorionic gonadotropin results giving rise to inappropriate therapy in a case of testicular cancer. J Urol 142: 1574–5PubMedGoogle Scholar
  44. 44.
    Kricka LJ (1999) Human anti-animal antibody interferences in immunological assays. Clin Chem 45: 942–56PubMedGoogle Scholar
  45. 45.
    Mazumdar M, Bacik J, Tickoo SK et al. (2003) Cluster analysis of p53 and Ki67 expression, apoptosis, alpha-foetoprotein, and human chorionic gonadotropin indicates a favorable prognostic subgroup within the embryonal carcinoma germ cell tumor. J Clin Oncol 21: 2679–88PubMedCrossRefGoogle Scholar
  46. 46.
    Brachmann AA, Beyer J, Jager R et al. (2003) Marked increase of the growth factors pleiotrophin and fibroblast growth factor-2 in serum of testicular cancer patients. Ann Oncol 14: 1525–9PubMedGoogle Scholar
  47. 47.
    Aubry F, Satie AP, Rioux-Leclercq N et al. (2001) MAGE-A4, a germ cell specific marker, is expressed differentially in testicular tumors. Cancer 92: 2778–85PubMedGoogle Scholar
  48. 48.
    Hechelhammer L, Storkel S, Odermatt B et al. (2003) Epidermal growth factor receptor is a marker for syncytiotrophoblastic cells in testicular germ cell tumors. Virchows Arch 443: 28–31PubMedCrossRefGoogle Scholar
  49. 49.
    Mandoky L, Geczi L, Bodrogi I et al. (2003) Expression of HER-2/neu in testicular tumors. Anticancer Res 23: 3447–51PubMedGoogle Scholar
  50. 50.
    Huyghe E, Matsuda T, Thonneau P (2003) Increasing incidence of testicular cancer worldwide: a review. J Urol 170: 5–11PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag France, Paris 2006

Authors and Affiliations

  • D. Bellet
    • 1
  • F. Troalen
    • 2
  1. 1.Service de biologie du Pr BelletInstitut Gustave-RoussyVillejuif Cedex
  2. 2.Institut Gustave RoussyVillejuif Cedex

Personalised recommendations